Dutton Associates Announces Investment Opinion: Patriot Scientific Rating And Price Target Maintained By Dutton Associates

Dutton Associates continues its coverage of Patriot Scientific (OTCBB: PTSC) maintaining its rating and price target at Speculative Buy and $.92 respectively. The 14-page report by Dutton senior analyst Richard W West, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. Patriot Scientific continues the business course that began in June 2005. After a change in top management, the Company began to execute its new strategy to become a dedicated intellectual property (IP) company by licensing its portfolio of microprocessor patents. In June 2005 Patriot Scientific ended its litigation surrounding patent ownership rights and established a partnership with TPL Group. Patriot Scientific/TPL, through November 30, 2007, granted licenses for the portfolio of microprocessor patents to over 30 major microprocessor manufacturers, either directly or through the partnership with TPL. Since May 2006, these licenses resulted in over $80.0 million in cash payments to Patriot and since November 30, 2007, has granted licenses for the portfolio of microprocessor patents to an additional eight microprocessor manufacturers for an undetermined amount. There are over 500 companies manufacturing products that make up this market potential. Patriot Scientific, through the commercialization agreement with Phoenix Digital, has served notice on approximately 300 companies that may possibly be infringing on one or more of the patents. Our update report reviews what we believe are the positive and negative aspects of Patriot. Based on a number of factors discussed in the report, we are reiterating our rating and target price. About Dutton Associates Dutton Associates is one of the largest independent investment research firms in the U.S. Its 30 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors. The cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. We received $35,000 from the Company for 4 Research Reports with coverage commencing on 11/27/2006. The Firm does not accept any equity compensation. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.